Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 28;13(19):4859. doi: 10.3390/cancers13194859

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

CD147 regulates LECs lymphangiogenic markers at transcriptional and translational levels. (a) qRT-PCR of FLT4, PROX1, LYVE1, and PDPN expression in LECs treated or not with rhCD147, using PPIA as a reference. Columns indicate the means of three independent experiments carried out in triplicate; bars indicate SD; * p < 0.05, ** p < 0.005, *** p < 0.0001. (b) Western blot analyses of VEGFR-3, PROX-1, LYVE-1, Podoplanin, and CD147 expression in total lysates of LECs treated or not with rhCD147. (c) Three independent Western blots were quantified for densitometry band analyses. Equal loading of proteins was assessed by probing for β-actin. Bars, SD; * p < 0.05, ** p <0.005, *** p < 0.0001. (d) Representative confocal images of PROX-1, LYVE-1 and Podoplanin immunofluorescent staining on LECs treated or not with rhCD147 (63X magnification). Scale bar: 30 µm. (e) ChIP-qPCR was performed on LECs treated or not with rhCD147, with antibody against PROX-1 total and control IgG. Columns indicate means of two independent experiments; and bars, SD; ns, non significant, * p < 0.05, ** p < 0.005, *** p < 0.0001.

CD147 regulates LECs lymphangiogenic markers at transcriptional and translational levels. (a) qRT-PCR of FLT4, PROX1, LYVE1, and PDPN expression in LECs treated or not with rhCD147, using PPIA as a reference. Columns indicate the means of three independent experiments carried out in triplicate; bars indicate SD; * p < 0.05, ** p < 0.005, *** p < 0.0001. (b) Western blot analyses of VEGFR-3, PROX-1, LYVE-1, Podoplanin, and CD147 expression in total lysates of LECs treated or not with rhCD147. (c) Three independent Western blots were quantified for densitometry band analyses. Equal loading of proteins was assessed by probing for β-actin. Bars, SD; * p < 0.05, ** p <0.005, *** p < 0.0001. (d) Representative confocal images of PROX-1, LYVE-1 and Podoplanin immunofluorescent staining on LECs treated or not with rhCD147 (63X magnification). Scale bar: 30 µm. (e) ChIP-qPCR was performed on LECs treated or not with rhCD147, with antibody against PROX-1 total and control IgG. Columns indicate means of two independent experiments; and bars, SD; ns, non significant, * p < 0.05, ** p < 0.005, *** p < 0.0001.